Last reviewed · How we verify
Bayer Acarbose
Acarbose inhibits intestinal alpha-glucosidase enzymes to slow the digestion and absorption of carbohydrates, reducing postprandial blood glucose spikes.
Acarbose inhibits intestinal alpha-glucosidase enzymes to slow the digestion and absorption of carbohydrates, reducing postprandial blood glucose spikes. Used for Type 2 diabetes mellitus, Postprandial hyperglycemia in type 2 diabetes.
At a glance
| Generic name | Bayer Acarbose |
|---|---|
| Sponsor | EMS |
| Drug class | Alpha-glucosidase inhibitor |
| Target | Alpha-glucosidase enzymes (intestinal brush border) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Acarbose is an alpha-glucosidase inhibitor that delays the breakdown of disaccharides and complex carbohydrates in the small intestine. By slowing carbohydrate absorption, it reduces the rate at which glucose enters the bloodstream after meals, thereby lowering postprandial glucose excursions in patients with diabetes. This mechanism helps improve glycemic control without stimulating insulin secretion.
Approved indications
- Type 2 diabetes mellitus
- Postprandial hyperglycemia in type 2 diabetes
Common side effects
- Gastrointestinal disturbances (flatulence, diarrhea, abdominal discomfort)
- Abdominal pain
- Diarrhea
- Hypoglycemia (when combined with other agents)
Key clinical trials
- Acarbose and Older Adults With Postprandial Hypotension (PHASE2)
- the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin (PHASE4)
- Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus (PHASE3)
- Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |